1. Report Introduction 2. Primary Ciliary Dyskinesia (PCD) Market Overview at a Glance 2.1. Market Share Distribution of Primary Ciliary Dyskinesia (PCD) in 2017 2.2. Market Share Distribution of Primary Ciliary Dyskinesia (PCD) in 2028 3. Disease Background and Overview: Primary Ciliary Dyskinesia (PCD) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Primary Ciliary Dyskinesia (PCD) in 7MM 4.3. Total Prevalent Patient Population of Primary Ciliary Dyskinesia (PCD) in 7MM – By Countries 5. Epidemiology of Primary Ciliary Dyskinesia (PCD) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) 5.1.3. Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) *Indication Specific 5.1.4. Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD)*Indication Specific 5.1.5. Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) 5.1.6. Treatable Cases of the Primary Ciliary Dyskinesia (PCD) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) 5.4.3. Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD)* 5.4.4. Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD)* 5.4.5. Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) 5.4.6. Treatable Cases of the Primary Ciliary Dyskinesia (PCD) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) 5.5.3. Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD)* 5.5.4. Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD)* 5.5.5. Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) 5.5.6. Treatable Cases of the Primary Ciliary Dyskinesia (PCD) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) 5.6.3. Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD)* 5.6.4. Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD)* 5.6.5. Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) 5.6.6. Treatable Cases of the Primary Ciliary Dyskinesia (PCD) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) 5.7.3. Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD)* 5.7.4. Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD)* 5.7.5. Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) 5.7.6. Treatable Cases of the Primary Ciliary Dyskinesia (PCD) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) 5.8.3. Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD)* 5.8.4. Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD)* 5.8.5. Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) 5.8.6. Treatable Cases of the Primary Ciliary Dyskinesia (PCD) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) 5.9.3. Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD)* 5.9.4. Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD)* 5.9.5. Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) 5.9.6. Treatable Cases of the Primary Ciliary Dyskinesia (PCD) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Primary Ciliary Dyskinesia (PCD) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Primary Ciliary Dyskinesia (PCD) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Primary Ciliary Dyskinesia (PCD): 7MM Market Analysis 12.1. 7MM Market Size of Primary Ciliary Dyskinesia (PCD) 12.2. 7MM Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) 12.3. 7MM Market Sales of Primary Ciliary Dyskinesia (PCD) by Products 13. Primary Ciliary Dyskinesia (PCD): Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Primary Ciliary Dyskinesia (PCD) in United States 13.1.2. Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) in United States 13.1.3. Market Sales of Primary Ciliary Dyskinesia (PCD) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Primary Ciliary Dyskinesia (PCD) in Germany 13.2.1.2. Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) in Germany 13.2.1.3. Market Sales of Primary Ciliary Dyskinesia (PCD) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Primary Ciliary Dyskinesia (PCD) in France 13.2.2.2. Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) in France 13.2.2.3. Market Sales of Primary Ciliary Dyskinesia (PCD) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Primary Ciliary Dyskinesia (PCD) in Italy 13.2.3.2. Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) in Italy 13.2.3.3. Market Sales of Primary Ciliary Dyskinesia (PCD) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Primary Ciliary Dyskinesia (PCD) in Spain 13.2.4.2. Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) in Spain 13.2.4.3. Market Sales of Primary Ciliary Dyskinesia (PCD) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Primary Ciliary Dyskinesia (PCD) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) in United Kingdom 13.2.5.3. Market Sales of Primary Ciliary Dyskinesia (PCD) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Primary Ciliary Dyskinesia (PCD) in Japan 13.3.2. Percentage Share of drugs marketed for Primary Ciliary Dyskinesia (PCD) in Japan 13.3.3. Market Sales of Primary Ciliary Dyskinesia (PCD) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in 7MM Table 2: Total Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Table 4: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Table 5: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Table 6: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Table 7: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Table 8: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Table 9: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Table 10: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Table 11: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Table 12: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Table 13: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Table 14: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Table 15: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Table 16: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Table 17: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Table 18: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Table 19: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Table 20: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Table 21: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Table 22: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Table 23: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Table 24: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Table 25: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Table 26: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Table 27: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Table 28: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Table 29: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Table 30: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Table 31: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Table 32: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Table 33: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Table 34: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Table 35: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Table 36: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Table 37: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 42:7MM- Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 43:7MM- Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 44: United States-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 45: United States-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 46: United States-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 47: Germany-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 48: Germany-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 49: Germany-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 50: France-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 51: France-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 52: France-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 53: Italy-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 54: Italy-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 55: Italy-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 56: Spain-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 57: Spain-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 58: Spain-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 59:UK-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 60:UK-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 61:UK-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 62: Japan-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Table 63: Japan-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Table 64: Japan-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 1: Total Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in 7MM Figure 2: Total Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Figure 4: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Figure 5: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Figure 6: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Figure 7: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in United States (2017-2028) Figure 8: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Figure 9: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Figure 10: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Figure 11: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Figure 12: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Germany (2017-2028) Figure 13: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Figure 14: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Figure 15: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Figure 16: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Figure 17: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in France (2017-2028) Figure 18: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Figure 19: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Figure 20: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Figure 21: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Figure 22: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Italy (2017-2028) Figure 23: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Figure 24: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Figure 25: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Figure 26: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Figure 27: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Spain (2017-2028) Figure 28: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Figure 29: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Figure 30: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Figure 31: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Figure 32: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in UK (2017-2028) Figure 33: Prevalent/Incident Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Figure 34: Sub-Type Specific cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Figure 35: Sex- Specific Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Figure 36: Diagnosed Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Figure 37: Treatable Cases of the Primary Ciliary Dyskinesia (PCD) in Japan (2017-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 42:7MM- Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 43:7MM- Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 44: United States-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 45: United States-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 46: United States-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 47: Germany-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 48: Germany-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 49: Germany-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 50: France-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 51: France-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 52: France-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 53: Italy-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 54: Italy-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 55: Italy-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 56: Spain-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 57: Spain-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 58: Spain-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 59:UK-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 60:UK-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 61:UK-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 62: Japan-Market Size of Primary Ciliary Dyskinesia (PCD) in USD MM (2017-2028) Figure 63: Japan-Market Share Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028) Figure 64: Japan-Market Sales of Primary Ciliary Dyskinesia (PCD) by Therapies in USD MM (2017-2028)